TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00663091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacteriophage
Description: WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing \< 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WPP-201 Bacteriophage
Description: WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing \< 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacteriophages
Description: WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing \< 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants.
Study: NCT02622282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Messages
Description: Text messages will be sent one time per day. Text messages will include messages to motivate and inform participants on the importance of walking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: Participants may receive a telephone call every two weeks for one month followed by once per month for two months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Handout
Description: Handout includes information specific to participant's condition and ways to promote an active lifestyle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handout
Description: Handout includes information specific to participant's condition and ways to promote an active lifestyle.
Study: NCT01673737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR260301
Description: Pharmaceutical form: film-coated tablets Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR260301
Description: Pharmaceutical form: film-coated tablets Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Pharmaceutical form: film-coated tablets Route of administration: oral
Study: NCT00561509

Intervention type: DRUG
Intervention: SSRIs
Description: Use within normal clinical practice

Intervention type: DRUG
Intervention: Dual antidepressants
Description: Use within clinical practice
Study: NCT01388335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: Administered orally
Study: NCT04148846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dypirone
Description: Dipyrone 2g, 6 / 6h for 7 days, orally or intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dypirone
Description: Dipyrone 2g, 6 / 6h for 7 days, orally or intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dypirone
Description: Dipyrone 2g, 6 / 6h for 7 days, orally or intravenous

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sphenopalatine block
Description: The sphenopalatine block will be performed with the patient in the supine position, with neck extended. Following topical anesthesia of the nasal vestibules with one application of 10% lidocaine spray and one application of 2% lidocaine gel in each nostril, two long cotton swab applicators embedded in 2% lidocaine jelly, one in each nostril, will be introduced. They will be advanced at a 45-degree angle to the floor of the nose until resistance is encountered, indicating that the swab is in the posterior nasopharyngeal wall, superior to the middle nasal concha. It will be held in this position for 5 minutes and then removed. Thereafter, a 14 gauge, non-cutting, teflon blunt catheter will be introduced into each nostril at a 45 ° angle to the hard palate until it touches the posterior wall of the nasopharynx. For it will be applied 2ml of 0.375% Ropivacaine, on each side, slowly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoprofen
Description: Ketoprofen 100 mg, 12 / 12h for 5 days, orally or intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoprofen
Description: Ketoprofen 100 mg, 12 / 12h for 5 days, orally or intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: Ketoprofen 100 mg, 12 / 12h for 5 days, orally or intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin 300 mg 8 / 8h for 7 days orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 300 mg 8 / 8h for 7 days orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 4mg 8 / 8h for 48h orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 4mg 8 / 8h for 48h orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline
Description: Theophylline 200mg, 12 / 12h, for 5 days, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: Theophylline 200mg, 12 / 12h, for 5 days, orally

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Espresso coffee
Description: Espresso coffee 20ml, 5x / day, for 7 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Espresso coffee
Description: Espresso coffee 20ml, 5x / day, for 7 days
Study: NCT01288261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bavituximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative study
Study: NCT02983552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPad®
Description: Binocular therapy using a Dig Rush application on an iPad®

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spectacle correction
Description: Spectacle correction for all waking hours, 7 days per week
Study: NCT00623142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen
Description: 100% Oxygen at 2.4 ATA for 30 minutes followed by 5 minutes break followed by 100% Oxygen at 2.4 ATA for another 30 minutes. This intervention was given about 4 to 5 hours prior to CABG
Study: NCT02869568

Intervention type: OTHER
Intervention: Data collection
Study: NCT02501577

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAD 1
Description: Placement and fiberoptic control

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAD 2
Description: Placement and fiberoptic control
Study: NCT04145518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium
Description: Participants will be randomized to take either a placebo pill or a single 550 mg naproxen sodium pill.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen Sodium
Description: Participants will be randomized to take either a placebo pill or a single 550 mg naproxen sodium pill.
Study: NCT01917630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALV003
Description: ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03532204

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients will received 2 courses of chemotherapy before SBRT if no hepatic or extra-hepatic progression identified.~All liver metastases will be irradiated. 4 doses prescription are allowed (according to the center, and the technique uded and the dosimetric constraints): 3x15 Gy, 4 x 15 Gy, 5 x10 Gy or 5 x 8 Gy.~The remaining courses of chemotherapy 2 to 3 weeks after completion of SBRT will be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: At investigator's discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: At investigator's discretion
Study: NCT03126513

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: G-POEM
Description: After confirmation of refractory gastroparesis, participants will undergo to gastric POEM. Participants will be admitted to hospital 24hrs before procedure and IV antibiotics will be given and then the procedure will be done. Technique consist of 4 steps: First: a submucosa injection of saline solution with methylene blue at 3-4cms from pylorus. Second: a submucosa incision and tunnel creation up to pyloric area. Third: Myotomy of the circular and longitudinal muscular layers of the pylorus and the antrum. Fourth: closure of the mucosal incision with hemoclips. After procedure they will be kept on surveillance and will be followed-up with clinical, endoscopic and scintigraphic studies up to 1 year after procedure.
Study: NCT05539898

Intervention type: DEVICE
Group type: OTHER
Intervention: ICD implantation
Description: All included in the study will undergo ICD implantation for primary prevention of SCD
Study: NCT04542317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH VN
Description: 4-6 sessions delivered over the course of 2-3 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced control
Description: A single session providing education about dementia
Study: NCT03963258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole-body vibration training
Description: The subjects were exposed to alternating vertical sinusoidal vibration using a Galileo tilting table system.The frequency of WBV ranged from 5 to 20 Hz, and the amplitude ranged from 1 to 6 mm.The subjects were kneeled on the ground, both shoulders flexed at 90 degrees, elbows slightly flexed, their trunk bent in this position and contacted on the platform board with their palms equidistant from the midpoint of the board

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional upper limb training
Description: compensatory techniques for activities of daily living, UE strength, therapist-guided techniques for facilitating normal UE movement patterns,and range of motion and traditional positioning
Study: NCT01526733

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human hyaluronidase PH20

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Insulin aspart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Insulin lispro

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Study: NCT05677568

Intervention type: DEVICE
Intervention: Carillon Mitral Contour System
Description: The Cardiac Dimensions Carillon Mitral Contour System (CMCS) is a medical device and consists of the following components:~1. A proprietary implant intended for permanent placement in the coronary sinus (CS)/great cardiac vein (GCV)~2. A catheter-based delivery system which consists of a curved CMCS delivery catheter (3.2mm outer diameter) and a handle assembly~3. A sizing catheter to enable the physician to estimate the overall CS/GCV dimensions so that an appropriately sized implant may be selected The implant is attached to the handle assembly and is delivered through the CMCS delivery catheter to the coronary vein along the posterolateral aspect of the mitral annulus. The implant is designed to re-shape the mitral annulus to reduce annular dilation and mitral regurgitation.

Intervention type: DEVICE
Intervention: Carillon Mitral Contour System
Description: The Cardiac Dimensions Carillon Mitral Contour System (CMCS) is a medical device and consists of the following components:~1. A proprietary implant intended for permanent placement in the coronary sinus (CS)/great cardiac vein (GCV)~2. A catheter-based delivery system which consists of a curved CMCS delivery catheter (3.2mm outer diameter) and a handle assembly~3. A sizing catheter to enable the physician to estimate the overall CS/GCV dimensions so that an appropriately sized implant may be selected The implant is attached to the handle assembly and is delivered through the CMCS delivery catheter to the coronary vein along the posterolateral aspect of the mitral annulus. The implant is designed to re-shape the mitral annulus to reduce annular dilation and mitral regurgitation.
Study: NCT02733640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: pantoprazole 40 mg once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: ranitidine 150 mg twice-daily
Study: NCT02481219

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PillCam® COLON 2 procedure-CONTROL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillCam® COLON 2 procedure-CONTROL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Senna tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Senna tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUPREP oral sulfate solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisacodyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUPREP oral sulfate solution with Gastrografin
Study: NCT02797938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taper guard tube
Description: Taper guard tube was intubated

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cylindrical tube
Description: Cylindrical tube was intubated
Study: NCT04342325

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infusion of ADR-001 (Mesenchymal stem cell)
Description: Once or twice with two week interval at a dose of 100 x 10 \^ 6 cells.
Study: NCT03754998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The participating dyads in intervention communities were invited to consume veo soup/meal (HSM) three times a week and provided weekly supply of iodized salt (450 g) for the household usage as well as being engaged in dry season container gardening. The veo soup/meal is a local Ghanaian soup/meal mainly made of Hibiscus Sabdarifa leaves. It is a soup when prepared a bit watery and consumed with 'tou zaafi' (millet or corn based cooked paste). It is also a meal when prepared thick and eaten by itself. The Hibiscus Sabdariffa leaves meal (HSM) used in the present study was made of 18 kg Hibiscus Sabdariffa leaves, 8 kg groundnut, 1.1 kg dawadawa (fermented African locust beans), 3 kg dried fish plus 0.045 kg iodized salt, cooked with about 23 L (23 kg) water to yield 52.5 kg HSM. In each community, groups of ten women took turns to share the cooking activities, washing of bowls, and making water available for cooking. No treatment provided in our control communities.
Study: NCT02664896

Intervention type: OTHER
Intervention: Knee Osteoarthritis
Description: Questionnaire completion, strength testing, gait testing, pressure-pain threshold testing, proprioception testing, knee measurements, blood draw, and knee radiographs.

Intervention type: OTHER
Intervention: Healthy Control
Description: Questionnaire completion, strength testing, gait testing, pressure-pain threshold testing, proprioception testing, and knee measurements.
Study: NCT02203968

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrinogen concentrate
Description: Six grams of fibrinogen concentrate (RiaSTAP™) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo Comparator: Normal saline Placebo (normal saline) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
Study: NCT02753504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT03239106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast 30 mg BID daily
Study: NCT00714870

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral nutrition and exercise program
Description: The intervention consists of a behavioral nutrition and exercise program. Meetings occur monthly on a Saturday afternoon and last 4 hours. During this time we cover: 1)registration: monitoring of sedentary activities and liquid choices, motivational interviewing, exercise testing;2)exercise: includes strength training; 3) educational lectures; 4) didactic games and projects.
Study: NCT01441232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211
Description: 400 mg of LX4211 administered as two 200 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211
Description: 400 mg of LX4211 administered as two 200 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Januvia®
Description: 100 mg Januvia® (sitagliptin) administered as one 100 mg sitagliptin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Januvia®
Description: 100 mg Januvia® (sitagliptin) administered as one 100 mg sitagliptin tablet
Study: NCT01140126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibody UB-421
Description: Single intravenous infusion at day 0 of a liquid dose of 1, 5, 10 or 25 mg/kg body weight.
Study: NCT02894684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aztreonam
Description: 14 days of AZLI: 75mg TDS PLUS IV Colistin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aztreonam
Description: 14 days of AZLI: 75mg TDS PLUS IV Colistin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: 14 days of IV Colistin plus one of Tazocin/Ceftazidime/Meropenem/Aztreonam/Fosfomycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: 14 days of IV Colistin plus one of Tazocin/Ceftazidime/Meropenem/Aztreonam/Fosfomycin
Study: NCT03949803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morning Chocolate Timing
Description: During two consecutive weeks volunteers will eat chocolate within 1 hour of their habitual wake-time (100g).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evening Chocolate Timing
Description: During two consecutive weeks volunteers will eat chocolate within 1 hours of habitual bedtime (100g).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Chocolate Timing
Description: During two consecutive weeks volunteers will not eat chocolate.
Study: NCT00721383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhancing Physical Activity Intervention
Description: Physical activity and caregiver skill-building

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CSBI
Description: Caregiver skill-building
Study: NCT01459497

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Image-Guided Radiation Therapy (IGRT)60 Gy in 15 fractions in 3 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiation
Description: Conventional radiation 60-66 Gy in 30-33 fractions in 6-7 weeks
Study: NCT00659789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vacc-4x
Description: Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: Sterile water is used in place of Vacc-4x and in place of Leukine
Study: NCT00030914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medroxyprogesterone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medroxyprogesterone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venlafaxine
Study: NCT03854279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tonsillar dissection
Description: The tonsils will be removed by bizact device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tonsillar dissection
Description: The tonsils will be removed by bizact device
Study: NCT04298671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga-Pilates
Description: As above
Study: NCT02853058

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: normal PI
Description: measurement of the PI in the uterine artery for pregnant women during labor, expressed in MoM

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: pathological PI
Description: measurement of the PI in the uterine artery for pregnant women during labor, expressed in MoM